Clinical Trial

Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy

Study acronym: LiBRA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. Primary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-20.
Status change: Not Yet Recruiting → Recruiting 2024-04-11
Trial Details
NCT Number NCT06051240
Lead Sponsor Region Stockholm
Collaborators: Rigshospitalet, Denmark
Conditions Cognitive Impairment, Cognitive Decline, Radiotherapy Side Effect, Radiotherapy; Complications, Brain Tumor, Memory Impairment, Late Effect of Radiation
Enrollment 84 participants
Start Date 2024-02-16
Primary Completion 2030-08-31 (estimated)
Study Completion 2033-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-12